Cytrx Corp : CytRx to Present at UBS Global Life Sciences Conference
09/17/2007| 08:30am US/Eastern
CytRx Corporation (NASDAQ:CYTR) a biopharmaceutical company engaged in
the development and commercialization of human therapeutics, today
announced that Steven A. Kriegsman, President and CEO, and Tod Woolf,
Ph.D., President and CEO of RXi Pharmaceuticals Corporation, CytRx's
majority-owned RNAi subsidiary, will present at the UBS Global Life
Sciences Conference on Monday, September 24 at 10:30 a.m. Eastern
time (7:30 a.m. Pacific time). This conference will be held at the Grand
Hyatt New York in New York City.
A live webcast of the presentation will be available on the CytRx Web
site at www.cytrx.com, and a replay
will be available for 90 days beginning approximately three hours after
the initial presentation.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company engaged in the development of high-value human therapeutics. The
Company owns three clinical-stage compounds based on its small molecule
"molecular chaperone" co-induction technology. In September 2006, CytRx
announced that arimoclomol was shown to be safe and well tolerated at
all three doses tested in its Phase IIa clinical trial in patients with
ALS. The Company plans to enter a Phase IIb clinical trial with
arimoclomol in ALS in 2007, subject to FDA clearance. The FDA has
granted Fast Track designation and Orphan Drug status to arimoclomol for
the treatment of ALS, which has also been granted orphan medicinal
product status for the treatment of ALS by the European Commission. The
Company has announced plans to commence a Phase II clinical trial for
arimoclomol in stroke recovery in the first half of 2008, subject to FDA
clearance. The Company has also announced plans to commence a Phase II
clinical trial with its next drug candidate, iroxanadine, for diabetic
foot ulcers in the first half of 2008, subject to FDA clearance. CytRx
has recently opened a research and development facility in San Diego.
For more information on the Company, visit www.cytrx.com.
About RXi Pharmaceuticals Corporation
Worcester, Massachusetts-based RXi Pharmaceuticals Corporation, a
majority-owned subsidiary of CytRx, is a biopharmaceutical research and
development company that focuses on developing RNAi-based therapeutics
for the treatment of human disease. RXi's initial focus is on
neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi
has licenses to a diverse series of early patents and patent
applications that were filed from 1998 to 2006 in the areas of RNAi
target sequences, RNAi chemistry and RNAi delivery. The Company was
founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel
Laureate for discovering RNAi and inventing RNAi therapeutics; Tariq M.
Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and
of RNAi nanotransporters; Greg Hannon, Ph.D., discoverer of RNAi
mechanism (RISC) and short hairpin RNAi (shRNAi); and Michael Czech,
Ph.D., a leader in the application of RNAi to diabetes and obesity.
RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized
STEALTH? RNAi, one of the most widely used
second-generation RNAi research products. For more information on RXi,
please visit www.rxipharma.com.
This press release may contain forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements involve risks and uncertainties that could
cause actual events or results to differ materially from the events or
results described in the forward-looking statements, including risks or
uncertainties described in CytRx's most recently filed SEC documents,
such as its most recent annual report on Form 10-K and any current
reports on Form 8-K filed since the date of the last Form 10-K. All
forward-looking statements are based upon information available to CytRx
on the date the statements are first published. CytRx undertakes no
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Dan Schustack, 212-732-4300
© Business Wire 2007